Clinical Study Assessing a New Scale to Measure Onset of Action in Generalized Anxiety Disorder

Completed · Not applicable · Has a placebo group

Conditions studied: Anxiety Disorders

In brief

The study is to assess the performance characteristics of a new measure to assess onset of efficacy in a GAD patient population.

Key facts

Study ID

NCT00715039

Run by

Pfizer

People needed

169

Starts

2003-10-01

Expected to finish

2004-05-01

Last updated by the study team

2008-10-03

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Primary Diagnosis of GAD (DSM IV, 300.02) as established by the clinician using all sources of data including the MINI structured interview
• HAM A score ³20 at the Screening (Study Day -7) and Baseline (Study Day 1) Visits by observer rating
• Good health as determined by medical history, physical examination, vital signs, electrocardiography (ECG), and clinical laboratory measurements
• Covi Anxiety Scale total score ³9 and Raskin Depression Scale total score £7 at the Screening Visit (to ensure predominance of anxiety symptoms over depression symptoms)
• Age 18 to 65 (inclusive)

You may not qualify if…

• Patients with most other current DSM-IV Axis I disorders.
• Patients with current or past schizophrenia, Psychotic disorder
• Delirium, dementia, amnestic, and other clinically significant cognitive disorders
• Bipolar or schizoaffective disorder
• Benzodiazepine abuse or dependence; and/or Factitious disorder.

Where it is running

• Pfizer Investigational Site — Glendale, California, United States
• Pfizer Investigational Site — Northridge, California, United States
• Pfizer Investigational Site — Orange, California, United States
• Pfizer Investigational Site — San Diego, California, United States
• Pfizer Investigational Site — Sherman Oaks, California, United States
• Pfizer Investigational Site — Van Nuys, California, United States
• Pfizer Investigational Site — Casselberry, Florida, United States
• Pfizer Investigational Site — Orlando, Florida, United States
• Pfizer Investigational Site — Atlanta, Georgia, United States
• Pfizer Investigational Site — Marietta, Georgia, United States
• Pfizer Investigational Site — Overland Park, Kansas, United States
• Pfizer Investigational Site — Overland Park, Kansas, United States
• Pfizer Investigational Site — Albuquerque, New Mexico, United States
• Pfizer Investigational Site — Albuquerque, New Mexico, United States
• Pfizer Investigational Site — Cincinnati, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.